IL238995A0 - A test to detect neutralizing autoantibodies for biological treatment - Google Patents

A test to detect neutralizing autoantibodies for biological treatment

Info

Publication number
IL238995A0
IL238995A0 IL238995A IL23899515A IL238995A0 IL 238995 A0 IL238995 A0 IL 238995A0 IL 238995 A IL238995 A IL 238995A IL 23899515 A IL23899515 A IL 23899515A IL 238995 A0 IL238995 A0 IL 238995A0
Authority
IL
Israel
Prior art keywords
assays
biologic therapy
detecting neutralizing
neutralizing autoantibodies
autoantibodies
Prior art date
Application number
IL238995A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,117 external-priority patent/US20130266963A1/en
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of IL238995A0 publication Critical patent/IL238995A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL238995A 2012-11-30 2015-05-25 A test to detect neutralizing autoantibodies for biological treatment IL238995A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732251P 2012-11-30 2012-11-30
US13/802,117 US20130266963A1 (en) 2011-07-06 2013-03-13 Assay for detecting neutralizing autoantibodies to biologic therapy
PCT/IB2013/060458 WO2014083520A2 (en) 2012-11-30 2013-11-27 Assays for detecting neutralizing autoantibodies to biologic therapy

Publications (1)

Publication Number Publication Date
IL238995A0 true IL238995A0 (en) 2015-07-30

Family

ID=50828561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238995A IL238995A0 (en) 2012-11-30 2015-05-25 A test to detect neutralizing autoantibodies for biological treatment

Country Status (13)

Country Link
EP (1) EP2926136A2 (enExample)
JP (1) JP2016502091A (enExample)
KR (1) KR20150088890A (enExample)
CN (1) CN105074461A (enExample)
AU (1) AU2013350817A1 (enExample)
BR (1) BR112015012482A2 (enExample)
CA (1) CA2892766A1 (enExample)
HK (1) HK1215969A1 (enExample)
IL (1) IL238995A0 (enExample)
MX (1) MX2015006852A (enExample)
RU (1) RU2015125739A (enExample)
SG (2) SG11201504097PA (enExample)
WO (1) WO2014083520A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010315547C1 (en) 2009-10-26 2015-06-04 Société des Produits Nestlé S.A. Assays for the detection of anti-TNF drugs and autoantibodies
AU2011317149B2 (en) 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
ES2735085T3 (es) 2014-12-05 2019-12-16 Nestle Sa Ensayos de cambio de movilidad homogéneos indirectos para la detección de agentes biológicos en muestras de pacientes
US11085931B2 (en) 2015-01-09 2021-08-10 W. Health L.P. Universal assay for determining the quantity of TNFα inhibitory drugs and their corresponding anti-drug-antibodies
EP3482199A1 (en) * 2016-07-08 2019-05-15 Atonomics A/S A universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples
AU2018241286B2 (en) 2017-03-31 2025-03-13 Ablynx N.V. Improved immunogenicity assays
JP7570421B2 (ja) * 2020-01-02 2024-10-21 エフ． ホフマン－ラ ロシュ アーゲー Ａｄａ応答特定アッセイ
CN111024958B (zh) * 2020-03-11 2020-06-23 同昕生物技术（北京）有限公司 用于检测单抗药物和抗单抗药物抗体的试剂及其应用
CN112730846B (zh) * 2020-12-18 2023-12-15 安渡生物医药(杭州)有限公司 一种用于小鼠血样检测免疫复合物的方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
CN117871856A (zh) * 2023-12-15 2024-04-12 首都医科大学附属北京地坛医院 可溶性因子在无症状神经梅毒检测中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010315547C1 (en) * 2009-10-26 2015-06-04 Société des Produits Nestlé S.A. Assays for the detection of anti-TNF drugs and autoantibodies
CN102884433A (zh) * 2010-04-29 2013-01-16 塞拉蒂亚戈公司 用于检测抗体的方法
AU2011317149B2 (en) * 2010-10-18 2015-05-07 Société des Produits Nestlé S.A. Methods for determining anti-drug antibody isotypes
ES2530175T3 (es) * 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
RU2013158256A (ru) * 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα

Also Published As

Publication number Publication date
WO2014083520A3 (en) 2014-07-31
RU2015125739A (ru) 2017-01-13
JP2016502091A (ja) 2016-01-21
MX2015006852A (es) 2015-09-16
WO2014083520A2 (en) 2014-06-05
BR112015012482A2 (pt) 2017-07-11
CN105074461A (zh) 2015-11-18
KR20150088890A (ko) 2015-08-03
SG11201504097PA (en) 2015-06-29
AU2013350817A1 (en) 2015-06-11
SG10201703210XA (en) 2017-06-29
CA2892766A1 (en) 2014-06-05
EP2926136A2 (en) 2015-10-07
HK1215969A1 (zh) 2016-09-30

Similar Documents

Publication Publication Date Title
IL238995A0 (en) A test to detect neutralizing autoantibodies for biological treatment
ZA201309703B (en) Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha
GB2521959B (en) Measurement system
LT3305918T (lt) Būdai, skirti epigenetinių sekų sudarymui
GB201222205D0 (en) Early entry
EP2932696A4 (en) ASSAY DEVICE
EP2801907A4 (en) MULTICOVER PROCESSOR SYSTEM
GB201322435D0 (en) Early Entry
GB201203938D0 (en) Assay system
PL2911534T3 (pl) Układ do wykrywania
GB201215571D0 (en) Assay method
ZA201407867B (en) Ore analysis system
GB201212528D0 (en) Assay
PL2639312T3 (pl) Oznaczenie immunologiczne do wykrywania miRNA
GB2503689B (en) Phosphate detection
GB201309275D0 (en) Early entry
GB201209664D0 (en) Assay device
GB201220465D0 (en) Foot measuring system
EP2844770A4 (en) MRM-MS SIGNATURE TEST
GB201216377D0 (en) Flooring system
GB201221011D0 (en) Assay method
GB201308983D0 (en) Early entry
GB201205626D0 (en) Biological reagent
GB201316110D0 (en) Phenylboronic Acid
GB201219024D0 (en) Assay